[go: up one dir, main page]

NO20024673L - Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin - Google Patents

Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin

Info

Publication number
NO20024673L
NO20024673L NO20024673A NO20024673A NO20024673L NO 20024673 L NO20024673 L NO 20024673L NO 20024673 A NO20024673 A NO 20024673A NO 20024673 A NO20024673 A NO 20024673A NO 20024673 L NO20024673 L NO 20024673L
Authority
NO
Norway
Prior art keywords
desglymidodrine
midodrine
oral use
release pharmaceutical
use containing
Prior art date
Application number
NO20024673A
Other languages
English (en)
Other versions
NO20024673D0 (no
Inventor
Annette Skinhoej
Peder Mohr Olsen
Poul Bertelsen
Original Assignee
Nycomed Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Austria Gmbh filed Critical Nycomed Austria Gmbh
Publication of NO20024673D0 publication Critical patent/NO20024673D0/no
Publication of NO20024673L publication Critical patent/NO20024673L/no

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20024673A 2000-03-31 2002-09-30 Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin NO20024673L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000549 2000-03-31
US20378300P 2000-05-12 2000-05-12
PCT/DK2001/000213 WO2001074334A1 (en) 2000-03-31 2001-03-29 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine

Publications (2)

Publication Number Publication Date
NO20024673D0 NO20024673D0 (no) 2002-09-30
NO20024673L true NO20024673L (no) 2002-11-27

Family

ID=26068806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024673A NO20024673L (no) 2000-03-31 2002-09-30 Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin

Country Status (10)

Country Link
EP (1) EP1267841B1 (no)
JP (1) JP2003528909A (no)
CN (1) CN1422150A (no)
AT (1) ATE283036T1 (no)
AU (1) AU2001246388A1 (no)
CA (1) CA2403886A1 (no)
DE (1) DE60107399D1 (no)
EE (1) EE200200556A (no)
NO (1) NO20024673L (no)
WO (1) WO2001074334A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089473A1 (en) * 2000-05-26 2001-11-29 Nycomed Austria Gmbh Pharmaceutical compositions comprising desglymidodrine as an active drug substance
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
JP7057365B2 (ja) * 2016-09-30 2022-04-19 ゼナメッド コーポレーション ミドドリンの組成物およびその使用方法
CN109937036A (zh) * 2016-10-21 2019-06-25 赛威蒂斯株式会社 包含米多君或其药学上可接受的盐作为有效成分的糖尿病及/或高血脂症的预防或治疗用药学组合物
EP3582765B1 (en) 2017-10-10 2021-04-28 Vertice Pharma, LLC Midodrine hydrochloride oral solution and uses thereof
JP7364568B2 (ja) * 2017-12-22 2023-10-18 ゼナメッド コーポレーション 持続放出ミドドリン塩酸塩組成物及び使用方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
KR102151051B1 (ko) * 2019-01-10 2020-09-02 고려대학교 산학협력단 당뇨병성 백내장 치료 또는 예방용 조성물
WO2022157633A1 (en) * 2021-01-20 2022-07-28 Cadila Healthcare Limited Enantiomerically pure desglymidodrine and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3417576A1 (de) * 1984-05-11 1985-11-14 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Retardformen des alpha-(2,5-dimethoxy-phenyl)-ss-glycinamidoaethanols und verfahren zu ihrer herstellung
AT383270B (de) * 1984-05-15 1987-06-10 Chemie Linz Ag Verfahren zur herstellung von oralen retardformen des alpha-(2,5-dimethoxy-phenyl)-betaglycinamido|thanols
EP0423484B1 (de) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Pressling mit retardierter Wirkstofffreisetzung

Also Published As

Publication number Publication date
WO2001074334A1 (en) 2001-10-11
EP1267841B1 (en) 2004-11-24
CN1422150A (zh) 2003-06-04
NO20024673D0 (no) 2002-09-30
CA2403886A1 (en) 2001-10-11
EP1267841A1 (en) 2003-01-02
DE60107399D1 (de) 2004-12-30
AU2001246388A1 (en) 2001-10-15
ATE283036T1 (de) 2004-12-15
EE200200556A (et) 2004-04-15
JP2003528909A (ja) 2003-09-30

Similar Documents

Publication Publication Date Title
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
EA200201044A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DK1663194T3 (da) Anvendelse af SAHA til behandling af mesotheliom
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
EP2248519A3 (en) Non-mucoadhesive film dosage forms
IS6557A (is) Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
NO20024673L (no) Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
RU2008110740A (ru) Твердые фармацевтические композиции, включающие 1-(4-хлоранилино)-4-(4-пиридилметил)фталазин и модификатор рн
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
CY1110659T1 (el) Χρησιμοποιηση toy saha για την θεραπευτικη αγωγη μεσοθηλιωματος
ATE462419T1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
HUP0302984A2 (hu) Buprenorphin felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
PT1337246E (pt) Utilizacao de compostos de 6-dimetilaminometil-1-fenilciclohexano para terapia da incontinencia urinaria
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
ATE399544T1 (de) Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application